Advances in ovarian cancer, from biology to treatment

McMullen, Michelle; Karakasis, Katherine; Rottapel, Robert; Oza, Amit M.

doi:10.1038/s43018-020-00166-5

Cited by 38 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer is the fourth-leading cause of death, and ovarian cancer is the second-leading cause of death in gynecologic cancers [1,2]. It is estimated that over 295,000 new diagnoses of ovarian cancer and over 184,799 associated deaths occur worldwide annually [3,4]. The standard treatment for ovarian cancer is exploratory surgery for primary staging or debulking, followed by six rounds of chemotherapy [5].…”

Section: Introductionmentioning

confidence: 99%

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

Yun

et al. 2022

IJMS

View full text Add to dashboard Cite

Anterior gradient protein 2 homolog (AGR2), an endoplasmic reticulum protein, is secreted in the tumor microenvironment. AGR2 is a member of the disulfide isomerase family, is highly expressed in multiple cancers, and promotes cancer metastasis. In this study, we found that etravirine, which is a non-nucleoside reverse transcriptase inhibitor, could induce AGR2 degradation via autophagy. Moreover, etravirine diminished proliferation, migration, and invasion in vitro. Moreover, in an orthotopic xenograft mouse model, the combination of etravirine and paclitaxel significantly suppressed cancer progression and metastasis. This drug may be a promising therapeutic agent for the treatment of ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

Yun

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The outcomes of ovarian cancer treatment are dependent on early diagnosis, appropriate surgery, and effective systemic therapy [ 1 , 12 ]. The clinical management of ovarian cancer includes debulking surgery, combination chemotherapy, radiation therapy, and other adjuvant therapies such as angiogenesis inhibitors in patients with suboptimally debulked and stage IV cancer, folate receptor targeting, and immunotherapy [ 1 , 5 , 6 , 9 – 11 ].…”

Section: Introductionmentioning

confidence: 99%

Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways

Huang

Zhao

Zhang

et al. 2021

Aging

View full text Add to dashboard Cite

Ovarian cancer is the third most common cancer and the second most common cause of gynecologic cancer death in women. Its routine clinical management includes surgical resection and systemic therapy with chemotherapeutics. While the first-line systemic therapy requires the combined use of platinum-based agents and paclitaxel, many ovarian cancer patients have recurrence and eventually succumb to chemoresistance. Thus, it is imperative to develop new strategies to overcome recurrence and chemoresistance of ovarian cancer. Repurposing previously-approved drugs is a cost-effective strategy for cancer drug discovery. The antiparasitic drug mebendazole (MBZ) is one of the most promising drugs with repurposing potential. Here, we investigate whether MBZ can overcome cisplatin resistance and sensitize chemoresistant ovarian cancer cells to cisplatin. We first established and characterized two stable and robust cisplatin-resistant (CR) human ovarian cancer lines and demonstrated that MBZ markedly inhibited cell proliferation, suppressed cell wounding healing/migration, and induced apoptosis in both parental and CR cells at low micromole range. Mechanistically, MBZ was revealed to inhibit multiple cancer-related signal pathways including ELK/SRF, NFKB, MYC/MAX, and E2F/DP1 in cisplatin-resistant ovarian cancer cells. We further showed that MBZ synergized with cisplatin to suppress cell proliferation, induce cell apoptosis, and blunt tumor growth in xenograft tumor model of human cisplatin-resistant ovarian cancer cells. Collectively, our findings suggest that MBZ may be repurposed as a synergistic sensitizer of cisplatin in treating chemoresistant human ovarian cancer, which warrants further clinical studies.

show abstract

“…There are four primitive histological subgroups of epithelial ovarian cancer (EOC): serous, endometrioid, mucinous, and clear cell [35]. Serous tumors are classified into two categories: high-grade serous carcinomas (HGSC) or low-grade serous carcinomas (LGSC) [36].…”

Section: Discussionmentioning

confidence: 99%

CircRNAs as potent biomarkers in ovarian cancer: a systematic scoping review

et al. 2021

View full text Add to dashboard Cite

More powerful prognostic and diagnostic tools are urgently needed for identifying and treating ovarian cancer (OC), which is the most fatal malignancy in women in developed countries. Circular RNAs (circRNAs) are conservative and stable looped molecules that can regulate gene expression by competing with other endogenous microRNA sponges. This discovery provided new insight into novel methods for regulating genes that are involved in many disorders and cancers. This review focuses on the dysregulated expression of circRNAs as well as their diagnostic and prognostic values in OC. We found that studies have identified twenty-one downregulated circRNAs and fifty-seven upregulated ones. The results of these studies confirm that circRNAs might be potent biomarkers with diagnostic, prognostic and therapeutic target value for OC. We also consider the connection between circRNAs and OC cell proliferation, apoptosis, metastasis, and chemotherapy resistance and sensitivity.

show abstract

Advances in ovarian cancer, from biology to treatment

Cited by 38 publications

References 15 publications

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways

CircRNAs as potent biomarkers in ovarian cancer: a systematic scoping review

Contact Info

Product

Resources

About